PRNewsWire
25 Mar 2026, 20:01 UTC · 26w ago
Verdict
Headline leans bearish. We score ADMA −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The investigation specifically focuses on the accuracy of ADMA's statements regarding accounting for revenue.
So whatAllegations of improper revenue accounting cut to the core of a company's financial integrity, raising the risk of earnings restatements and severely undermining investor confidence in the stock's valuation.
More negative than 99% of claims this week
Ademi LLP is investigating possible securities fraud claims against ADMA Biologics regarding inaccurate statements about its financial statements, business operations, and prospects.
Continue reading
5 related stories
More negative than 94% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
Which stocks this story touches
More negative than 94% of ticker scores this week
The company is being investigated for possible securities fraud and inaccurate financial statements regarding revenue.
More negative than 94% of ticker scores this week
The company is being investigated for possible securities fraud resulting from inaccurate statements.
More negative than 84% of ticker scores this week
The company is being investigated for possible breaches of fiduciary duty regarding the fair price for public shareholders.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
+5.1%
Price is moving against the score
$10.12 vs $9.63 close before publication (Mar 25) · not market-adjusted
ADMA chart →
